NGM Aims For Three Drugs In Clinical Trials, Padded By Cash From Merck

Privately held NGM Biopharmaceuticals is investing in another dozen preclinical compounds, fueled in part by a rich deal with Merck & Co. that also enables employee expansion, Jeff Jonker explains in interview.